Table 4 Odds ratio for risk of being HCV RNA negative among European American and African American injection drug users, by MBL2 secretor haplotype profile.

-618

-289

-65

Ex1 -34

Ex1 -27

Ex1 -18

G

G

C

C

G

G

32.3%

29.2%

33.2%

0.24

referent

C

G

T

C

G

G

21.2%

18.5%

22.1%

0.23

0.93 (0.58–1.51)

C

C

C

C

G

G

19.5%

25.2%

17.7%

0.01

1.73 (1.10–2.74)

C

G

C

C

A

G

12.9%

11.5%

13.3%

0.49

0.93 (0.53–1.64)

G

G

C

T

G

G

6.5%

6.9%

6.4%

0.66

1.19 (0.59–2.39)

C

G

C

C

G

G

5.1%

5.0%

5.1%

0.94

0.92(0.40–2.13)

C

G

T

C

G

A

2.5%

3.9%

2.0%

0.08

3.27 (1.18–9.05)

0.14

C

G

T

C

G

G

27.3%

24.8%

28.0%

0.38

referent

C

G

T

C

G

A

25.7%

27.0%

25.3%

0.69

1.24 (0.76–2.01)

C

G

C

C

G

G

16.5%

18.4%

15.9%

0.49

1.24(0.70–2.21)

C

C

C

C

G

G

15.4%

15.6%

15.4%

0.89

1.23 (0.69–2.18)

G

G

C

C

G

G

10.7%

9.8%

10.9%

0.74

1.10 (0.57–2.12)

C

G

C

C

A

G

3.4%

3.4%

3.4%

0.91

1.15 (0.44–3.01)

G

G

C

T

G

G

1.0%

1.1%

1.0%

0.92

1.21 (0.23–6.29)

0.98